Articles On Imugene (ASX:IMU)

The Australian dollar and bond yields slid after the Reserve Bank of Australia lifted the cash rate by 0.25% on Melbourne Cup Day, to 4.35%. It was the first change to the official rate in five months – and the first under new governor Mich...

It was only on Tuesday that we got the latest look at ASX 200 bank share Westpac Banking Corp (ASX: WBC)'s full-year results for FY2023. As we went through at the time, it was a pretty pleasing set of numbers from the ASX 200 bank share. W...

Shortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Bank of Australia lifted the cash rate once again – by 25 basis points to 4.35 per cent for November. The decision was in line with expert...

The Westpac Banking Corp (ASX: WBC) share price is having a poor session on Tuesday. In afternoon trade, the banking giant's shares are down 2% to $21.48. Should you buy the Westpac share price dip? The broker community is largely undecide...

The S&P/ASX 200 Index (ASX: XJO) is under pressure ahead of the Reserve Bank's meeting. In afternoon trade, the benchmark index is down 0.4% to 6,967.3 points. Four ASX shares that are falling more than most today are listed below. H...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small gain. The benchmark index rose 0.3% to 6,997.4points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expected to f...

Warren Buffett is called the Oracle of Omaha for good reason. Atop his phenomenal investing success, the 93-year-old CEO of Berkshire Hathaway (NYSE: BRK.A) is well known for sharing his market acumen with eager disciples across the world....

Owners of Westpac Banking Corp (ASX: WBC) shares will soon be getting their FY23 final dividend payment after the bank released its FY23 report. It was a successful period for the ASX bank share – the business reported a 26% increase in...

The S&P/ASX 200 Index (ASX: XJO) has started the week positively. In afternoon trade, the benchmark index is up 0.3% to 6,998.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they are stormi...

Highlights To date, 34 heavily treated patients administered with CF33-hNIS All treatments have been ascertained tolerable and safe Trial expansion is planned for ten patients with bile duct cancer Shares of Imugene Limited (ASX:...

Imugene has recorded positive early signals from the first phase of its metastatic advanced solid tumour clinical trial evaluating the safety and efficacy of its novel cancer-killing virus known as “Vaxinia”.

A Phase 1 metastatic advanced solid tumours (MAST) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA) has delivered positive early signals for immuno-oncology company Imugene (ASX: IMU). The study str...

The Imugene Ltd (ASX: IMU) share price is soaring higher today. Shares in the ASX biotechnology company closed on Friday trading for 4.8 cents. At the time of writing, shares are changing hands for 5.3 cents apiece, up 10.4%. For some con...

PYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial Cleo’s CleoDX Triage Test was published in ‘Cancer’ journal   PYC to commence human trials in 2024 after...

The Whispir Ltd (ASX: WSP) share price is shooting the lights out on Monday. The ASX tech share closed on Friday trading for 30 cents. At the time of writing, shares are swapping hands for 48 cents apiece, up a whopping 60%. Here's why inv...

Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus.

Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus.

Highlights Phase 1 MAST trial has cleared cohort 4 of the IV arm of the monotherapy and IV cohort 2 of combination study. The study is evaluating the safety of VAXINIA, novel cancer-killing virus CF33-hNIS. Next cohort is open in IV a...

Imugene (ASX:IMU) reaches the next cohort in the IV arm of its monotherapy dose escalation study, and also its combination study for the cancer-killing virus, Vaxinia As a result, cohort five of the IV arm for the monotherapy dose escala...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33hNIS (VAXINIA) has cleared cohort 4 of t...

ASX-listed medtech Imugene has dosed the first patient with its novel immunotherapy drug candidate “onCARlytics” which has the potential to target and eradicate solid tumours.

Althea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlytics Phase 1 trial on solid tumours   Althea’s cannabis oil approved for reimbursement Cannabis company Althea Group (ASX:AGH) has announced...

Imugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlytics, has commenced a Phase 1 clinical trial, with the first patient now dosed.

Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on show at what it says is the world’s most influential oncology platform.

Imugene (ASX:IMU) announces that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy CHECKVacc are being showcased at the ESMO Congress this week in Madrid IMU is a clinical-stage immuno-oncology company, that aims to cont...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The US FDA has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer treatment after transferring an investigational new drug application to the company from Precision Biosciences.

The US Food and Drug Administration (FDA) has transferred an investigational new drug (IND) application for allogeneic CD19 CAR T azer-cel from Precision Biosciences Inc to Imugene (ASX: IMU). The transfer follows Imugene’s acquisition of a...

World Overnight SPI Overnight 7055.00 – 13.00 – 0.18% S&P ASX 200 7030.30 – 7.90 – 0.11% S&P500 4274.51 + 0.98 0.02% Nasdaq Comp 13092.85 + 29.24 0.22% DJIA 33550.27 – 68.61 – 0.20% S&P500 VIX 18.22 – 0.72 – 3.80%...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark index is down 0.5% to 7,043.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are pushing...

It hasn't been a great day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this Tuesday. At the time of writing, the ASX 200 has slipped by 0.71%. But that hasn't stopped one ASX exchange-traded fund (ETF) from hitting...

Another day, another set of 52-week highs for ASX uranium shares! Most uranium miners are rising on Tuesday, in contrast to the rest of the market. The S&P/ASX 200 Energy Index (ASX: XEJ) started the day higher but is now down 0.19%...

It's been a pretty awful start to this Tuesday's trading for the S&P/ASX 300 Index (ASX: XKO) and ASX 300 shares so far today. At present, the ASX 300 has slipped by 0.32% and is back to around 7,000 points. So given this slip for the...

The S&P/ASX 200 Index (ASX: XJO) has delighted investors hoping for a reprieve from the share market today with a green session. After falling every single trading day last week, the ASX...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Monday. In afternoon trade, the benchmark index is down 0.2% to 7,057 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:...

Cancer fighter Imugene has positioned itself as one of the most cashed-up med-techs on the ASX after raising a further $18.2 million from a share placement plan (SPP) to add to a previous $35 million placement.

The TechnologyOne Ltd (ASX: TNE) share price is starting the week strongly. At the time of writing, the ASX 200 tech share is up 2.5% to $15.65. This compares favourably to the performance of the ASX 200 index, which is down 0.35%. Why is...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has raised $18.2 million from a share purchase plan component of a capital raising exercise to fund the acquisition of worldwide licensing rights for lead candidate azer-cel to targe...

World Overnight SPI Overnight 7186.00 – 14.00 – 0.19% S&P ASX 200 7196.60 – 33.80 – 0.47% S&P500 4443.95 – 9.58 – 0.22% Nasdaq Comp 13678.19 – 32.05 – 0.23% DJIA 34517.73 – 106.57 – 0.31% S&P500 VIX 14.11 + 0.11 0....

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The ASX 200 benchmark falls 0.5% as central bank boogeymen spook investors Energy pretty much on its own out front of the rest of the sectors Small caps led by lithium and new metal minnows with some sturdy new finds   Local markets hav...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

The S&P/ASX 200 Index (ASX: XJO) had another shaky day on Tuesday. Yesterday seemed to show that investors couldn't decide what they wanted out of the markets, with stints on both positive and ne...

Clinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for its “PD1-Vaxx” that is currently in the development stage of a bid to target non-small cell lung cancer.

Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a new patent by the Japanese Patent Office for its PD1-Vaxx clinical candidate. The grant protects the immunotherapeutic drug, which is a first-in-class programmed d...

Highlights Imugene’s first-in-class programmed death-1 (PD1) vaccine, PD1-Vaxx has been granted a Japanese patent. The patent extends protection to the matter composition and treatment method in cancer. Imugene Limited (ASX: IMU) h...

Imugene Limited (ASX: IMU) stock is in great demand with investors on Tuesday. In morning trade, the beaten-down biotech share is up almost 7% to 6.3 cents. Why is Imugene stock rising? Investors have been buying the biotech's shares after...

Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new patent for its PD1-Vaxx clinical drug candidate.

Futures point to the ASX opening modestly higher, bolstered by gains on Wall Street overnight. Overnight, Tesla shares surged 10 per cent in a vote of confidence for artificial intelligence, boosting the Nasdaq. Back home, here are so...